Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma

ConclusionFrom the perspective of the Chinese healthcare system, nivolumab was not as cost-effective as placebo for relapsed malignant mesothelioma.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research